Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 105,365 shares traded hands during trading, an increase of 247% from the previous session's volume of 30,375 shares.The stock last traded at $7.78 and had previously closed at $7.21.
Separately, HC Wainwright reiterated a "buy" rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a research report on Wednesday.
Read Our Latest Analysis on Aligos Therapeutics
The firm's fifty day moving average is $10.75 and its two-hundred day moving average is $13.69. The firm has a market cap of $706.90 million, a P/E ratio of -6.32 and a beta of 2.16.
Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The firm had revenue of $1.06 million for the quarter. During the same period in the previous year, the firm posted ($10.75) EPS. As a group, sell-side analysts forecast that Aligos Therapeutics, Inc. will post -8.2 EPS for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC grew its stake in Aligos Therapeutics by 17.6% in the first quarter. Acadian Asset Management LLC now owns 657,995 shares of the company's stock worth $644,000 after purchasing an additional 98,628 shares during the period. Opaleye Management Inc. boosted its holdings in shares of Aligos Therapeutics by 25.7% during the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company's stock valued at $1,597,000 after buying an additional 333,000 shares in the last quarter. Finally, Armistice Capital LLC grew its position in shares of Aligos Therapeutics by 5.3% in the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company's stock worth $2,540,000 after buying an additional 363,000 shares during the period. Hedge funds and other institutional investors own 60.43% of the company's stock.
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Aligos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aligos Therapeutics wasn't on the list.
While Aligos Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.